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Proximal correlates of metabolic phenotypes during ‘at-risk’ and
‘case’ stages of the metabolic disease continuum
MT Haren1,2,3, G Misan4, JF Grant5, JD Buckley6, PRC Howe7, AW Taylor8, J Newbury9 and RA McDermott10
OBJECTIVE: To examine the social and behavioural correlates of metabolic phenotypes during ‘at-risk’ and ‘case’ stages of the
metabolic disease continuum.
DESIGN: Cross-sectional study of a random population sample.
PARTICIPANTS: A total of 718 community-dwelling adults (57% female), aged 18--92 years from a regional South Australian city.
MEASUREMENTS: Total body fat and lean mass and abdominal fat mass were assessed by dual energy x-ray absorptiometry.
Fasting venous blood was collected in the morning for assessment of glycated haemoglobin, plasma glucose, serum
triglycerides, cholesterol lipoproteins and insulin. Seated blood pressure (BP) was measured. Physical activity and smoking,
alcohol and diet (96-item food frequency), sleep duration and frequency of sleep disordered breathing (SDB) symptoms, and
family history of cardiometabolic disease, education, lifetime occupation and household income were assessed by questionnaire.
Current medications were determined by clinical inventory.
RESULTS: 36.5% were pharmacologically managed for a metabolic risk factor or had known diabetes (‘cases’), otherwise were
classified as the ‘at-risk’ population. In both ‘at-risk’ and ‘cases’, four major metabolic phenotypes were identified using principal
components analysis that explained over 77% of the metabolic variance between people: fat mass/insulinemia (FMI); BP;
lipidaemia/lean mass (LLM) and glycaemia (GLY). The BP phenotype was uncorrelated with other phenotypes in ‘cases’, whereas
all phenotypes were inter-correlated in the ‘at-risk’. Over and above other socioeconomic and behavioural factors, medications
were the dominant correlates of all phenotypes in ‘cases’ and SDB symptom frequency was most strongly associated with FMI,
LLM and GLY phenotypes in the ‘at-risk’.
CONCLUSION: Previous research has shown FMI, LLM and GLY phenotypes to be most strongly predictive of diabetes
development. Reducing SDB symptom frequency and optimising the duration of sleep may be important concomitant
interventions to standard diabetes risk reduction interventions. Prospective studies are required to examine this hypothesis.
Nutrition and Diabetes (2012) 2, e24; doi:10.1038/nutd.2011.20; published online 16 January 2012
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INTRODUCTION
A considerable proportion of obese individuals do not co-express
metabolic risk (metabolically healthy obese) and a considerable
proportion of normal weight individuals express multiple meta-
bolic risk factors (metabolically unhealthy lean).1 In both obese
and lean individuals, the main predictors of metabolic ill-health in
the U.S. NHANES were older age and lower participation in leisure-
time physical activity.1
The co-expression of metabolic traits vary both in nature (the
traits that co-express) and in magnitude (the level to which they
express) across individuals and populations,2 - 5 and likely result
from interactions between genetic and environmental factors,
which have not been fully characterised.4,6 Understanding the
specificity of socio-economic and behavioural determinants of
metabolic trait co-expression at different stages of the metabolic
disease continuum may aid in tailoring diabetes prevention and
management programs to individuals and communities with
particular metabolic trait or risk profiles.
Current understandings of the social and behavioural determi-
nants of metabolic status have come from studies, which use
either individually measured risk factors or metabolic syndrome
classifications as outcomes.7 - 9 The former approach may be
limited by the inability to account for the co-expression of
metabolic traits in individuals and the clinical dichotomy of the
latter excludes examination of either the nature or the magnitude
of trait co-expression.
Standardised definitions for metabolic phenotypes (such as
metabolically healthy obese and metabolically unhealthy lean) do
not exist, which limits the comparability of findings across studies,
and if they did, they would have the same limitations as
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definitions for metabolic syndrome. Since 1994 a substantial
literature has emerged from factor or principal components
analysis (PCA)10 that has identified four canonical (accepted) latent
(underlying/unmeasured) metabolic factors (phenotypes) in the
pathophysiology of diabetes: body/fat mass/insulinemia (FMI)
glycaemia (GLY), lipidaemia and blood pressure (BP).11 - 13 Despite
these phenotypes being studied as determinants of diabetes,12 to
our knowledge no studies have extensively examined the social
and behavioural determinants of phenotype expression.
The objective of this study was to examine the specificity of
social and behavioural correlates of latent metabolic phenotypes
during ‘at-risk’ and ‘case’ stages of the metabolic disease
continuum. The study aimed to confirm the presence of the
canonical latent factors and to examine their social and
behavioural correlates in ‘at-risk’ and ‘case’ sub-populations.
PARTICIPANTS AND METHODS
Research context
The Whyalla Intergenerational Study of Health (WISH) is a
population-based cohort recruited between February 2008 and
July 2009, within the city of Whyalla, an industrial outer regional
city that is located on the eastern Eyre Peninsula of South
Australia.14 The city had a population of over 22 000 in 2006.
When compared with South Australia and Australia overall,
Whyalla has a workforce enriched with blue-collar workers, and
the demand for such occupations may explain the higher
proportion of adults who had not completed year 12 of high
school (or equivalent). The proportion of UK/Irish born and people
of Australian Aboriginal or Torres Strait Islander origin appear
higher than in South Australia and Australia overall.14
Previous investigations of the health of this population
have revealed obesity,15 asthma,15,16 chronic lung disease,15,16
chronic liver disease and lung cancer16 to be higher in Whyalla
than in South Australia overall, or demographically and geogra-
phically comparative communities. A previous ecological study
suggested that behavioural risk factors were unable to explain the
apparent poorer respiratory and hepatic health outcomes in this
population.16
Sampling and Recruitment
Whyalla households (n¼ 2500) were randomly selected from the
residential housing database of the State Planning Authority. The
strength of this sampling frame was the completeness, however,
approach and recruitment was a complex multi-stage process
because of limited contact information in the databases
(residential address only). This novel sampling frame was used
instead of telephone listings (Electronic White Pages) owing to a
high proportion of households without landline telephone
connections in the city. Invitations to participate were mailed to
‘The Householder’ co-ordinated with a community-wide media
campaign informed by a Community Advisory Group. House-
holders were invited to register online or by telephone, providing
their telephone number and basic demographic information. One
hundred seventy-eight (7%) households responded to this
approach. The second stage successfully matched 1183 household
addresses in the sample to names and telephone numbers in the
Electronic White Pages. Third, remaining unmatched households
were approached by door knocking, a minimum of two attempts
to contact were made and calling cards were left.
Once telephone numbers were obtained, Computer Assisted
Telephone Interviewing technology was used to recruit the adult
(X18 years) in each household who last had their birthday (‘index
adult’), and to collect demographic, health and risk factor data and
schedule clinical assessments. Interviews were conducted by
trained interviewers under established protocols.17 Participants
provided written informed consent at the time of clinical
assessment. Protocols and procedures were approved by the
Human Research Ethics Committee of The University of South
Australia and the Aboriginal Health Research Ethics Committee of
South Australia.
Definitions of ‘at-risk’ and ‘case’ stratification
‘At-risk’ was defined as the absence of both known diabetes and
pharmacological management with diabetes or cardiovascular
system agents (Anatomical Therapeutic Classification codes A10,
C01-C03 and C07-C10). ‘Case’ was defined as diagnosed diabetes
or management with the aforementioned therapeutic classes.
Major outcome measures
Body composition was assessed using DXA (Lunar Prodigy,
GE Medical Systems, Madison, WI, USA) with the manufacturer’s
software (enCORE 2003 version 7.52). Scans were performed
according to the manufacturer’s protocols with participants’
supine. Total fat and lean masses (g) were determined auto-
matically from the manufacturer’s software. Total abdominal and
intra-abdominal fat masses were determined by defining two
regions of interest in the abdomen by drawing quadrilateral boxes
with the base touching the top of the iliac crest, the upper
margins touching the most inferior aspect of the ribs and the
lateral borders extending to the edge of the abdominal soft tissue
for total abdominal fat, and the inner border of the rib cage for
intra-abdominal fat.
Fasting, morning venous blood samples were collected
(B40ml) and assayed by a National Association of Testing
Authorities accredited laboratory. Fasting plasma glucose con-
centration was measured using a Chemistry analyser system
(Olympus AU5400, Olympus Optical C Ltd, Japan) with inter-assay
CVs of 2.41% at 3.41mmol l1 and 2.21% at 19.72mmol l1. HbA1c
was assayed by cation-exchange high pressure liquid chromato-
graphy using instrumentation, kits and reagents from Bio-Rad
laboratories (Hercules, CA, USA) with inter-assay CVs of 2.4% at
A1c of 5.7 and 2.2% at A1c of 10.0. Fasting serum triglycerides and
cholesterol lipoproteins were determined enzymatically using a
Roche Hitachi 911 chemistry analyser (Roche, Boehringer,
Germany) with inter-assay CV’s of: 2.63% at 2.44mmol l1 and
3.16% at 1.0mmol l1 of triglyceride; 2.05% at 5.83mmol l1 and
2.83% at 2.55mmol l1 of total cholesterol; 3.29% at 2.04mmol l1
and 3.2% at 0.9mmol l1 of high-density lipoprotein (HDL)
cholesterol. Fasting serum insulin concentration was measured
in serum collected, separated and frozen at 80 1C within 2 h of
collection. Radioimmunoassay was performed on an Abbott
Architect immunoassay analyser (Abbott Park, IL, USA) with
inter-assay CVs of 7.81% at 8.44mU l1, 5.87% at 57.44mU l1
and 8.53% at 97.90mU l1. Systolic and diastolic BP were
measured using an automatic sphygmomanometer (Welch Allyn
Spot Vital Signs 420 Series, Skaneateles Falls, NY, USA). Two
measurements were taken after the participant had been seated
and rested for 5 and 10min. A third measurement was taken if
readings differed by more than 10%. The mean of the two
readings or the median of three readings was calculated for both
pressures. Height was determined to within 1mm using a wall
stadiometer (Surgical and Medical Products No. 26SM, Mentone
Education Supplies, Melbourne, Australia), body mass was
measured to the nearest 100 g with an electronic scale (Tanita
BF-681, Tanita, Arlington Heights, IL, USA) and waist circumference
was measured twice to the nearest 0.5mm using a steel girth tape
(Lufkin W606PM) and the mean value obtained. A third measure-
ment was taken if the two varied by greater than 1%, and the
median was used.18 Body mass index (BMI) was calculated as
weight (kg)/height (m2).
For comparison with national prevalence data, abdominal
obesity was classified as waist circumference X102 cm for males
and X88 cm for females and general obesity was classified as
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BMIX30 kgm2.19 Elevated systolic and diastolic BP were defined
as X140 and X90mmHg, respectively.20 Elevated fasting
triglyceride concentrations were defined as X2.0mmol l1 and
low HDL cholesterol was defined as p1.0mmol l1.20 Impaired
fasting glucose was defined as a fasting plasma glucose
concentration 45.5mmol l1(ref.21) and diabetes was indicated
by a fasting plasma glucose concentration 47mmol l1.20
Undiagnosed diabetes was defined as having a fasting plasma
glucose concentration 47mmol l1 without having reported a
previous diagnosis of diabetes.
Metabolic phenotype expression scores
Intra-abdominal, abdominal and total fat masses, total lean mass,
fasting serum concentrations of triglycerides, HDL and insulin,
fasting plasma concentration of glucose, HbA1c, seated systolic and
diastolic BP were subject to PCA for dimension reduction to the
latent factors. This analysis assigned a score to each participant
representing how strongly they expressed each latent phenotype.
Independent variables
Similarly, the consumption frequencies for ninety-six food and
beverage items collected using an updated version (version 3.1) of
the Australian Cancer Council of Victoria’s Dietary Questionnaire22
were entered into a PCA for dimension reduction to latent dietary
patterns, which assigned a score to each participant representing
how strongly their diet reflected each of the identified patterns.
From the same questionnaire, alcohol consumption was com-
puted in grams. Smoking status was defined as never-, past- and
current-smoker. Total time spent in leisure-time physical activities
(LTPA) was determined by questionnaire. Intensity weights (3.5 for
walking, 5.0 for moderate and 7.5 for vigorous intensity exercise)
were used to compute metabolic equivalent hours (MET-h), where
o1600 MET-h/week was defined as sedentary or low; and41600
MET-h/week as moderate to high physical activity.23 Average
hours spent sleeping each day was self reported. Owing to
evidence that both short and long sleep durations are associated
with increased risk of diabetes,24 sleep duration was categorised
as short (o7 h per day) or long (X9 h per day) sleep and
examined relative to normal sleep duration (7 --o9 h per day).
A sleep disordered breathing (SDB) symptom score (range 0--12)
was computed as the sum of symptom frequency from zero
(never) to four (44 times per week) for three symptoms: snorting
or gasping; loud snoring; and breathing cessation, choking or
struggling for breath during sleep. Family history (parents and
grandparents) of diabetes, high BP, stroke and heart disease were
obtained by self-report. Pictograms25 were used to estimate
maternal and paternal somatotypes at age 40 years. Fifteen year
retrospective somatotyping of parents, by offspring, using these
pictograms, correlated highly with previously measured height
and weight.26 Educational attainment was categorised as Bachelor
degree or higher, high school or vocational certificate, or did not
complete high school. Lifetime primary occupation was coded
according the Australian and New Zealand Classification of
Occupations and reduced to ‘Manager/professional’, ‘White collar
worker’ and ‘Blue collar worker’. Gross annual household income
was collected in approximate $20 000 increments and reduced to
three categories of $40 000 increments for analysis.
Standard population data
Baseline data from the Australian Obesity Diabetes and Lifestyle
(AusDiab) Study, a stratified sample of adults 25 years and over
from 42 randomly selected Census Collector Districts in Australia
in 1999--2000 (n¼ 11 247, pseudo-response rate 55%),27 were
used to estimate standardised prevalence ratios (SPR) for
cardiometabolic risk factors in the study population.
Australian and South Australian behavioural risk factor data
from the 2007--08 Australian National Health Survey28 were used
to estimate SPRs for behavioural risk factors in the study
population.
Statistical analysis
Data analysis was performed using STATA 10.1 for Windows
(StataCorp., College Station, TX, USA). For population prevalence
estimates, data were weighted to the age and sex distribution
of the Estimated Residential Population of Whyalla in 2007(ref. 29)
and the likelihood of being recruited into the study, as per the
equation: weight¼ hhld_adult (bnh/lnh) (ln/bn); where hhld_adult
is the number of people aged 18 and over (adults) residing in the
household; bnh is the adult population size of Whyalla by sex and
age-group; bn is the total adult population of Whyalla; lnh is the
adult sample size of WISH by sex and age-group; and ln is the total
adult sample size of the WISH cohort. For SPRs, the stratum-
specific prevalence estimates from the national standard popula-
tion data (AusDiab and Australian National Health Survey) were
used to calculate the expected number of cases in the study
population (WISH). Expected cases were summed across strata,
and compared with the number of observed cases, the SPR was
calculated as the ratio of observed to expected cases.
PCA with oblique rotation (oblimin) was used to define the
principal latent metabolic phenotypes and the principal latent
dietary patterns in the population. Components were maintained
for further analysis based on Eigen values41 (see Supplementary
Information, Figure 1) and limited to four for interpretability.
To minimise the likelihood of over-specifying the number of
components, potentially outlying and influential observations
were examined using scatter-plots and bi-plots of the first and last
two components as suggested by Jolliffe.30 Components scores
were standardised for further analysis.
Hierarchical, multivariate (multiple outcomes) regression was
used to model the associations of age, sex, education, lifetime
primary occupational class, household income, family history of
cardiometabolic disease, dietary pattern scores, alcohol consump-
tion, past and current smoking, moderate-high LTPA, sleep
duration and SRB symptoms with latent phenotypes.
RESULTS
Participants
The participant flow and response rates are summarised in
Figure 1. Overall, 32.2% of eligible adults participated in the
clinical study. Married people were over-represented by B20%
and divorced/separated people and those who had never married
were under-represented by B10%. The sample was 10% over-
represented by adults who owned their residences or rented
privately and 10% under-represented by those renting from the
State Housing administration. There was an B5% over-represen-
tation of adults born in the UK and Ireland and a 1.5% under-
representation of Aboriginal or Torres Strait Islanders (data not
shown).
Table 1 describes the metabolic, behavioural and socio-economic
characteristics of the ‘At-risk’ and ‘Case’ sub-populations by sex. The
prevalence of both abdominal obesity (48.4% (95% CI 44.152.7%))
and low HDL cholesterol (17.7% (95% CI 14.221.8%)) was higher
than national estimates (SPR for abdominal obesity 1.6 (95% CI
1.41.8), SPR for low HDL cholesterol 1.3 (95% CI 1.11.6)). All
other metabolic risk markers were equivalent to the national
prevalence. Hypertension prevalence was 31.3% (95% CI
27.735.1%); 8.7% (95% CI 6.711.4%) were untreated and
55.8% (95% CI 47.663.7%) were adequately controlled below
140/90mmHg. The prevalence of hypertriglyceridaemia was
22.1% (95% CI 18.825.9%). After excluding diabetes that was
only associated with pregnancy (13 cases), the prevalence of self-
reported doctor-diagnosed diabetes was 7.5% (95% CI 5.89.8%).
Four percent (4.3%) of the population had biochemical evidence
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of diabetes (fasting plasma glucose X7mmol l1) at clinical
assessment. Based on self-reported diagnoses and biochemical
evidence, the estimated prevalence of likely undiagnosed
diabetes was 1.5% resulting in an estimated population preva-
lence for total diabetes of 9.1% (95% CI 7.111.6%). This equated
to one undiagnosed diabetic for every 5 diagnosed cases in
Whyalla. The estimated population prevalence of impaired fasting
glucose was 6.4% (95% CI 4.59.2%). The prevalence of moderate-
high LTPA (35.0% (95% CI 30.839.2%)) was significantly higher
than the national prevalence (SPR 1.3 (95% CI 1.11.5)). Current
smoking (23.0% (95% CI 19.626.7%)), past smoking (28.6% (95%
CI 25.132.4%)) and never smoking (48.4% (95% CI 44.152.8%))
were similar to national and state estimates.
Latent metabolic phenotypes and dietary factors
Four latent metabolic phenotypes were confirmed in both ‘at-risk’
and ‘case’ groups: FMI; BP; lipidaemia/lean mass (LLM) and GLY
(Table 2). Moderate correlations existed between all latent
phenotypes except for BP in ‘cases’, which was uncorrelated with
the other phenotypes. Four latent dietary patterns were identified
that are described as: Mediterranean; Fruit; Anglo; and Junk (See
Supplementary data file).
Socio-economic, familial and behavioural correlates
The covariate-adjusted models of phenotype expression in ‘at-risk’
and ‘case’ sub-populations are shown in Tables 3 and 4,
respectively (see Supplementary data file for the sequential
models). In the ‘at-risk’ strata, high school and/or vocational
education and a unit increase in SDB symptom score were
associated with a 0.51 and 0.11 s.d. increase in FMI expression,
respectively. Blue-collar occupation and a unit increase in the
maternal endomorphic-ectomorphic scale were associated with a
0.38 s.d. and 0.13 s.d. decrease. In ‘cases’, a 1-year age increase
and long sleep was associated with a 0.03 s.d. and 0.56 s.d.
decrease, and taking diuretics with a 0.62 s.d. increase in FMI
expression.
In the ‘at-risk’, female gender and current smoking were
associated with a 0.84 s.d. and 0.35 s.d. decrease in BP expression,
respectively. A 1-year age increase was associated with a 0.02 s.d.
increase. In ‘cases’, a one unit increase in ‘fruit’ diet pattern score
was associated with a 0.08 s.d. increase, and taking diuretics with a
0.60 s.d. decrease in BP expression.
In the ‘at-risk’, female gender, household income up to $40 000
p.a. and a 100 g per month increase in alcohol consumption (10
Australian standard drinks) were associated with a 1.17 s.d., 0.28
s.d. and 0.01 s.d. decrease in LLM expression, respectively. Current
Figure 1. Participation flowchart. Reprinted with permission of SA Health from Haren et al.14
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Table 1. Metabolic, behavioural and socio-economic characteristics of the ‘at-risk’ and ‘cases’, by sex
At-risk Cases
Men Women Men Women
Mean (s.d.) range of n 170- 201 221 - 255 81 - 107 119 --155
Age (years) 45.26 (13.62) 42.11 (14.04) 62.15 (12.18) 59.24 (14.94)
Waist circumference (cm) 96.61 (13.54) 88.99 (13.99) 107.34 (13.59) 97.44 (16.34)
Body mass index (kgm2) 27.57 (5.35) 27.88 (6.04) 30.62 (5.59) 31.44 (7.92)
Fasting serum triglyceride (mmol l1) 1.67 (1.03) 1.26 (0.63) 1.88 (1.12) 1.56 (0.83)
Fasting serum HDL (mmol l1) 1.29 (0.3) 1.55 (0.41) 1.23 (0.26) 1.49 (0.39)
Fasting serum insulin (mU l1) 10.1 (8.41) 8.66 (6.31) 14.43 (10.75) 12.32 (10.03)
Fasting plasma glucose (mmol l1) 5.34 (0.68) 4.89 (0.48) 6.22 (1.95) 5.39 (1.04)
Fasting glycated haemoglobin (%) 5.47 (0.49) 5.32 (0.44) 6.07 (1.09) 5.73 (0.67)
Systolic BP (mmHg) 125.29 (13.97) 115.65 (12.4) 135.67 (17.91) 130.75 (18.42)
Diastolic BP (mmHg) 78.98 (8.59) 74.42 (7.36) 80.61 (8.98) 78.09 (9.3)
Intra-abdominal fat mass (g) 1907.24 (1152.2) 1681.7 (825.37) 2708.57 (1095.23) 2057.25 (950.84)
Abdominal fat mass (g) 2384.73 (1512.57) 2474.49 (1300.23) 3276.12 (1451.72) 2945.34 (1490.96)
Total body fat mass (g) 24 053.86 (12009) 30 909.23 (11 918.13) 31 058.41 (11 613.22) 36 071.47 (134 66.33)
Total body lean mass (g) 56 895.56 (8085.45) 40 167.74 (5356.88) 57 874.64 (9158.44) 41 269.17 (8074.74)
FMI metabolic factora, standard units 0.08 (1.11) 0.07 (0.9) 0.19 (1) 0.14 (0.98)
BP metabolic factora, standard units 0.49 (0.96) 0.39 (0.85) 0.22 (0.96) 0.15 (1)
LLM metabolic factora, standard units 0.67 (0.85) 0.53 (0.77) 0.53 (0.89) 0.37 (0.90)
GLY metabolic factora, standard units 0.32 (1.11) 0.25 (0.82) 0.34 (1.24) 0.24 (0.70)
Mediterranean diet factor, standard units 0.01 (0.98) 0.13 (0.98) 0.28 (0.96) 0.02 (1.06)
Fruit and yoghurt diet factor, standard units 0.36 (0.99) 0.11 (0.94) 0.16 (0.85) 0.42 (1.02)
Anglo (meat and three vegetables) diet factor,
standard units
0.15 (0.94) 0.12 (0.96) 0.17 (1) 0.28 (1.08)
Junk diet factor, standard units 0.43 (1.03) -0.05 (0.96) 0.08 (0.85) 0.43 (0.91)
Alcohol (g per month) 524.94 (1472.64) 447.12 (1946.26) 276.67 (420) 169.73 (681.73)
Sleep duration (h per day) 7.16 (1.17) 7.37 (1.35) 7.33 (1.69) 7.15 (1.33)
Normal sleep duration (7 - 9 h per day), n(%) 115.00 (57.21) 148.00 (58.04) 49.00 (45.79) 74.00 (47.13)
Short sleep duration (o7h per day), n(%) 60.00 (29.85) 65.00 (25.49) 34.00 (31.78) 49.00 (31.21)
Long sleep duration (X9 h per day), n(%) 16.00 (7.96) 30.00 (11.76) 16.00 (14.95) 14.00 (8.92)
SDB, symptom frequency score (0--12) 1.24 (2.17) 0.9 (2.01) 1.69 (2.95) 1.03 (2.07)
Somatotype at 40 (mother), 9-point scale 5.29 (1.46) 5.15 (1.54) 5.17 (1.34) 4.88 (1.53)
Somatotype at 40 (father), 9-point scale 5.34 (1.46) 5.3 (1.71) 5.66 (1.55) 5.59 (1.61)
No. (%)
Highest education level
Bachelor degree+ 31 (15.42) 51 (20) 10 (9.35) 11 (7.01)
Completed HS/vocational qualification 118 (58.71) 115 (45.1) 60 (56.07) 53 (33.76)
Did not complete HS 51 (25.37) 86 (33.73) 37 (34.58) 88 (56.05)
Missing 1 (0.5) 3 (1.18) 0 (0) 5 (3.18)
Lifetime primary occupational class
Managers and professionals 46 (22.89) 73 (28.63) 18 (16.82) 32 (20.38)
White collar employees 18 (8.96) 95 (37.25) 14 (13.08) 58 (36.94)
Blue collar employees 134 (66.67) 65 (25.49) 74 (69.16) 46 (29.3)
Missing 3 (1.49) 22 (8.63) 1 (0.93) 21 (13.38)
Household income
4$80 000 p.a. 65 (32.34) 73 (28.63) 20 (18.69) 17 (10.83)
$40 001 to $80 000 p.a. 84 (41.79) 96 (37.65) 25 (23.36) 30 (19.11)
Up to $40 000 p.a. 52 (25.87) 86 (33.73) 62 (57.94) 105 (66.88)
Missing 0 (0) 5 (3.18)
Family history (positive)
Diabetes 54 (26.87) 103 (40.39) 30 (28.04) 50 (31.85)
Heart disease 87 (43.28) 127 (49.8) 64 (59.81) 81 (51.59)
Stroke 61 (30.35) 73 (28.63) 32 (29.91) 45 (28.66)
High blood pressure 91 (45.27) 133 (52.16) 41 (38.32) 72 (45.86)
Missing 2 (1.87) 6 (3.82)
Current smoker 63 (31.34) 71 (27.84) 14 (13.08) 25 (15.92)
Past smoker 55 (27.36) 73 (28.63) 59 (55.14) 59 (37.58)
Moderate to high LTPA 85 (42.29) 92 (36.08) 45 (42.06) 34 (21.66)
Self-reported diagnosed diabetes 0 (0) 0 (0) 37 (34.58) 35.00 (22.29)
Missing 3 (2.8) 11 (7.01)
Undiagnosed diabetes, FPGX7mmol l1 5 (2.49) 5 (1.96) 2.00 (1.87) 1.00 (0.64)
Missing 16.00 (14.95) 9.00 (5.73)
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smoking and a unit increase in SDB symptom score were
associated with a 0.31 s.d. and 0.05 s.d. increases, respectively.
In ‘cases’, female gender and a 1-year age increase were
associated with a 1.34 s.d. and 0.02 s.d. decrease in LLM
expression, respectively. Lipid-lowering medications were not
associated with LLM expression.
In the ‘at-risk’, female gender and blue-collar occupation were
associated with a 0.51 s.d. and 0.28 s.d. decrease in GLY
expression, respectively. A 1-year age increase, a 1 unit increase
in SDB symptom score and short sleep duration were associated
with a 0.03 s.d., 0.05 s.d. and 0.38 s.d. increase, respectively. In
‘cases’, being female was associated with a 0.40 s.d. decrease and
family history of diabetes, moderate-high LTPA, short sleep and
taking medication for diabetes were associated with a 0.37 s.d.,
0.41 s.d., 0.34 s.d. and 1.06 s.d. increase in GLY expression,
respectively.
DISCUSSION
Metabolic health profile of the population
Almost one in two adults in the study population had abdominal
obesity, which, when standardised to 10-year old Australian
national estimates, represented 1.6 cases to every case nationally.
Despite the excess of abdominal obesity, which may be expected
given the age of the reference data, the prevalence of diabetes,
hypertriglyceridaemia and hypertension were equivalent to
estimates from the same national data. This suggests that
metabolic risk in Whyalla was either well controlled or had not
emerged from the observed abdominal obesity. Whyalla had
higher prevalence of controlled and lower prevalence of untreated
hypertension suggesting that the incongruence between abdom-
inal obesity and hypertension may be due to improvements in
detection and management over the past decade, as has been
demonstrated internationally.31 Improved pharmacological man-
Table 1 (Continued )
At-risk Cases
Men Women Men Women
Medications
Diabetes (ATC A10) 0 (0) 0 (0) 27 (25.23) 17 (10.83)
Cardiac therapy (ATC C01) 0 (0) 0 (0) 10 (9.35) 6 (3.82)
Antihypertensives (ATC C02) 0 (0) 0 (0) 9 (8.41) 5 (3.18)
Diuretics (ATC C03) 0 (0) 0 (0) 17 (15.89) 20 (12.74)
Beta blocking agents (ATC C07) 0 (0) 0 (0) 22 (20.56) 18 (11.46)
Calcium channel blockers (ATC C08) 0 (0) 0 (0) 19 (17.76) 23 (14.65)
Renin--angiotensin system (ATC C09) 0 (0) 0 (0) 64 (59.81) 78 (49.68)
Lipid modifying agents (ATC C10) 0 (0) 0 (0) 56 (52.34) 77 (49.04)
Total 201 (100) 255 (100) 107 (100) 157 (100)
Abbreviations: ATC, anatomical therapeutic classification, BP, blood pressure; FMI, fat mass/insulinemia; FPG, fasting plasma glucose; GLY, glycaemia; HDL, high-
density lipoprotein; LLM, lipidaemia/lean mass; LTPA, leisure-time physical activities; p.a., per annum; SDB, sleep disordered breathing. aDerived separately for
‘at-risk’ and ‘case’ sub-populations.
Table 2. Component loadings for original metabolic variables with oblique rotation of components in the ‘at-risk’ and ‘case’ sub-populations
Component number At-risk Cases
1 2 3 4 1 2 3 4
FMI BP LLM GLY FMI GLY LLM BP
Fasting serum triglyceride 0.03 0.04 0.47 0.08 0.07 0.07 0.70 0.07
Fasting serum HDL 0.02 0.11 0.70 0.03 0.03 0.06 0.61 0.14
Fasting serum insulin 0.34 0.02 0.16 0.13 0.22 0.23 0.17 0.06
Fasting serum glucose 0.00 0.09 0.03 0.65 0.01 0.67 0.01 0.01
Fasting HbA1c 0.01 0.07 0.03 0.74 0.01 0.68 0.03 0.01
Systolic BP 0.04 0.70 0.03 0.03 0.04 0.09 0.06 0.70
Diastolic BP 0.04 0.66 0.00 0.04 0.04 0.09 0.05 0.69
Intra-abdominal fat mass 0.50 0.07 0.08 0.02 0.52 0.06 0.03 0.04
Abdominal fat mass 0.55 0.01 0.01 0.00 0.55 0.00 0.04 0.01
Total body fat mass 0.57 0.06 0.10 0.05 0.54 0.11 0.09 0.05
Total body lean mass 0.00 0.21 0.51 0.02 0.29 0.09 0.31 0.10
Percentage of variance 29.2 17.8 16.0 14.0 30.4 18.9 15.0 14.9
Correlation coefficients
Component 1 1.000 1.000
Component 2 0.268 1.000 0.268 1.000
Component 3 0.313 0.232 1.000 0.275 0.228 1.000
Component 4 0.196 0.229 0.298 1.000 0.019 0.037 0.067 1.000
Abbreviations: BP, blood pressure; FMI, fat mass/insulinemia; GLY, glycaemia; HbA1c, haemoglobin A1 c; HDL, high-density lipoprotein; LLM, lipidaemia/lean
mass. Loadings further than |0.30| from zero were considered a major contributor to the component and are shown in bold. Oblique rotation was
applied to components, allowing correlation between the components. The percentage of variance is that of the original 11 variables, which is accounted
for by each component.
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agement may also explain the incongruent hyperlipidemia
prevalence, however, it is unlikely to explain the incongruent
impaired fasting glucose and diabetes prevalence as the use of
insulin sensitising or beta-cell preserving agents for diabetes
prevention is not yet widespread despite emerging positive
evidence.32 - 34 The prevalence of moderate-high LTPA was higher
than the contemporary national prevalence, which may confer
metabolic risk reduction independent of fat loss.35,36 Under-
standing the determinants of this (and other) particular commu-
nity metabolic profiles has implications for the design of diabetes
prevention programs.
This study examined the dominant metabolic pheno-
types, their coexpression patterns and their associations with
socio-economic characteristics, health-related behaviours and
family cardiometabolic health history in ‘at-risk’ and ‘case’
sub-populations. The dominance of the widely accepted under-
lying metabolic phenotypes, similar to those previously
described in diabetics and non-diabetics12 were confirmed in
this population. GLY and FMI phenotypes have been shown to
predict diabetes equivalently to NCEP defined metabolic
syndrome; LLM is slightly inferior and BP has the lowest
predictive value.12 Consistent with this finding, the BP pheno-
type in ‘cases’ was uncorrelated with the other phenotypes,
and in counter distinction with the GLY phenotype, explained
less of the metabolic variance in the ‘case’ versus ‘at-risk’
sub-population.
Table 3. Social, family history and behavioural associates of latent metabolic phenotype scores in the ‘at-risk’ sub-population
FMI BP LLM GLY
Coefficient 95% CI Coefficient 95% CI Coefficient 95% CI Coefficient 95% CI
At-risk
Female 0.108 0.149, 0.364 0.835*** 1.075, 0.596 1.169*** 1.389, 0.948 0.514*** 0.771, 0.257
Age (years) 0.001 0.011, 0.009 0.020*** 0.010, 0.029 0.009* 0.017, 0.000 0.027*** 0.017, 0.037
Education
Bachelor degree or
higher
Referent Referent Referent Referent
HS-vocational
qualification
0.507*** 0.166, 0.848 0.254 0.065, 0.573 0.203 0.091, 0.497 0.045 0.296, 0.387
Less than HS certificate 0.286 0.144, 0.715 0.287 0.114, 0.689 0.018 0.352, 0.388 0.098 0.332, 0.529
Lifetime 11 occupational class
Manager/professional Referent Referent Referent Referent
White collar 0.227 0.567, 0.114 0.040 0.278, 0.358 0.049 0.343, 0.244 0.117 0.458, 0.223
Blue collar 0.382** 0.697, 0.066 0.081 0.377, 0.214 0.148 0.420, 0.124 0.282* 0.598, 0.035
Household income, gross p.a.
Greater than $80 000 Referent Referent Referent Referent
$40 001 to $80 000 0.036 0.210, 0.282 0.029 0.259, 0.202 0.047 0.166, 0.259 0.081 0.327, 0.166
Up to $40 000 0.090 0.410, 0.229 0.012 0.287, 0.311 0.295** 0.570, 0.019 0.154 0.474, 0.166
Somatotype at 40
(mother)
0.128*** 0.203, 0.053 0.012 0.058, 0.082 0.008 0.073, 0.056 0.024 0.098, 0.051
Somatotype at 40 (father) 0.010 0.080, 0.059 0.016 0.049, 0.082 0.017 0.043, 0.077 0.026 0.045, 0.096
Family history, diabetes 0.222* 0.014, 0.458 0.163 0.057, 0.384 0.048 0.155, 0.252 0.038 0.198, 0.274
Family history, CHD 0.062 0.155, 0.278 0.095 0.297, 0.107 0.052 0.134, 0.239 0.064 0.281, 0.153
Family history, stroke 0.072 0.157, 0.300 0.062 0.152, 0.276 0.047 0.245, 0.150 0.068 0.161, 0.297
Family history,
hypertension
0.024 0.244, 0.196 0.060 0.266, 0.146 0.080 0.270, 0.109 0.182 0.038, 0.402
Diet, Mediterranean 0.013 0.159, 0.133 0.069 0.067, 0.206 0.080 0.206, 0.046 0.076 0.071, 0.222
Diet, fruit and yoghurt 0.108 0.251, 0.034 0.032 0.166, 0.101 0.043 0.166, 0.080 0.098 0.241, 0.045
Diet, Anglo (meat and
three vegetables)
0.108 0.032, 0.248 0.081 0.212, 0.050 0.088 0.033, 0.209 0.083 0.224, 0.057
Diet, junk 0.009 0.106, 0.123 0.030 0.077, 0.137 0.003 0.096, 0.102 0.015 0.099, 0.130
Alcohol (g per month) 0.000 0.000, 0.000 0.000 0.000, 0.000 0.000*** 0.000, 0.000 0.000 0.000, 0.000
Smoking, current 0.266** 0.528, 0.003 0.351*** 0.596, 0.105 0.308*** 0.082, 0.535 0.175 0.088, 0.438
Smoking, past 0.121 0.116, 0.358 0.080 0.142, 0.301 0.193* 0.011, 0.398 0.160 0.398, 0.077
LTPA, mod-high 0.209* 0.427, 0.010 0.001 0.203, 0.206 0.089 0.100, 0.277 0.077 0.142, 0.296
Sleep duration
Normal sleep Referent Referent Referent Referent
Short sleep 0.163 0.069, 0.395 0.188* 0.029, 0.405 0.136 0.336, 0.064 0.380*** 0.148, 0.612
Long sleep 0.092 0.295, 0.478 0.176 0.186, 0.538 0.192 0.141, 0.526 0.131 0.257, 0.519
SDB, symptom score 0.112*** 0.061, 0.163 0.020 0.028, 0.068 0.047** 0.003, 0.091 0.052** 0.001, 0.104
R-squared (observed) 0.248 (313) 0.312 (313) 0.453 (313) 0.277 (313)
Abbreviations: BP, blood pressure; CHD, coronary heart disease; CI, confidence intervals; FMI, fat mass/insulinemia; GLY, glycaemia; LLM, lipidaemia/lean mass;
LTPA, leisure-time physical activities; p.a., per annum; SDB, sleep disordered breathing. Data presented are regression coefficients and 95% CI. Data were
modelled using multivariate regression, which adjusts for the correlation structure of the four PCA-derived phenotypes (outcome variables). ***Po0.001,
**Po0.01, *Po0.1.
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Correlates of metabolic phenotypes in ‘cases’: implications for
management
These differences likely reflect the impact of pharmacological
regulation of metabolic traits in ‘cases’ as opposed to physiolo-
gical regulation in the ‘at-risk’. The absence of associations
between phenotype expression and medication may indicate
successful treatment to target, that is, those taking medication
have, on average, the same phenotype expression as those not
taking medication. This was the case for lipid modifying agents,
but not diuretics, which were strongly associated with lower BP
and higher FMI expression, suggesting that they lower BP below
the untreated average and increase fat mass and fasting insulin
above the untreated average. Diuretics such as amiloride can raise
fasting insulin37 and may predict type 2 diabetes in people with
impaired glucose tolerance.38 In particular, thiazide diuretics
increase hepatic fat content and c-reactive protein, both of which
are associated with reduced insulin sensitivity.39 Thus, while
diuretics may lower BP, they can have adverse metabolic effects,
in particular reducing insulin sensitivity. In contradistinction,
diabetic medication was associated with higher GLY expression
(and therefore, failure to achieve normoglycaemia). Lowering
glucose concentrations to normal in diabetics, however, may not
be the treatment goal as the benefits versus risks of aggressive
management are still unclear.40,41 Similarly, moderate-high LTPA
was not associated with GLY expression in the ‘at-risk’, but was
associated with higher expression in ‘cases’, suggesting that it fails
to downregulating expression to normoglycaemia in ‘cases’.
In both ‘at-risk’ and ‘cases’, moderate-high LTPA was inversely
associated with FMI expression, consistent with studies, which
have shown improvements in fat mass and insulin regulation
across the metabolic disease continuum42,43 through increasing
cardiorespiratory fitness.44 As moderate-high LTPA was associated
with the lower FMI expression only, it does not explain the
incongruence between abdominal obesity and metabolic risk in
this population. Instead, the higher prevalence of self-reported
moderate-high LTPA may reflect greater perceived exertion due to
physical activities in the less metabolically fit.45 This highlights the
importance of physical activity for secondary prevention during
progression along the metabolic disease continuum.
Interestingly, long sleep was associated with a more favourable
FMI expression in ‘cases’, which is consistent with the mounting
evidence that sleep curtailment promotes weight gain and the
onset of obesity.46 Current clinical trials in obese individuals aim to
investigate the effect of extending sleep duration on obesity and
cardiometabolic risk factor trajectories.47 Consistent with studies
showing and increased likelihood of having diabetes in short and
long sleepers,48,49 short sleep in this study was associated with
less favourable GLY expression in both ‘cases’ and ‘at-risk’
subpopulations. This suggests a negative impact on glucose
regulation throughout the metabolic disease continuum or
alternatively, shortened sleep as a result of even sub-clinical
derangements in glycaemic regulation. The association between
sleep duration, obesity and glycaemic dysregulation is potentially
mediated by an increase in appetite.50 Intervening on diet and
exercise in overweight people with Impaired Glucose Tolerance
improve body weight and insulin sensitivity to similar degrees in
both short and long sleepers, but appeared to produce greater
reductions in the incidence of type 2 diabetes in long sleepers.51
Correlates of metabolic phenotypes in the ‘at-risk’: implications for
prevention
Of all the socio-economic, family history and behavioural variables
examined, the frequency of SDB symptoms was the only variable
associated with multiple phenotypes, after adjustment for sleep
duration and other covariates. More frequent symptoms were
associated with greater expression of FMI, LLM and GLY
phenotypes, suggesting that these modifiable symptoms may
be partly responsible for phenotype co-expression, leading to
greater risk of diabetes. Consistent with this interpretation, the BP
phenotype, which holds the lowest predictive value for future
diabetes,12 was not associated with SDB in ‘at-risk’ adults.
Associations of clinically defined SDB with glucose intolerance
and insulin resistance have been previously reported.52 Although
there are fewer than 20 prospective studies in this field, current
evidence suggests that SDB may be a prevalent cause of
diabetes53,54 and poor glycaemic control in diabetics, which can
be ameliorated by continuous positive airway pressure therapy.55
Both SDB symptoms and risk of diabetes are modifiable by weight
loss in very fat people.56 The causal role of SDB in dyslipidaemia is
less clear.57
In addition, mid-level education, family history of diabetes and
maternal adiposity were major correlates of FMI expression in the
‘at-risk’. Higher adherence to the ‘fruit’ and ‘Anglo’ diet patterns
were associated with lower GLY expression, however, this was not
independent of family history, other behaviours or SDB. These
findings are contrary to those of other studies linking Mediterra-
nean diet to reduced risk of metabolic syndrome.58 This may be
owing to differences in what this dietary pattern represents locally
versus in the international literature on ‘Mediterranean diet’.
Higher alcohol consumption and not being a current smoker were
associated with lower LLM expression, consistent with the
beneficial effect of alcohol consumption on increasing HDL
cholesterol59 and negative effects on muscle mass and function.60
The strengths of this study include the metabolic characterisa-
tion of participants, particularly the use of DXA to quantify fat and
lean masses. Limitations include the characterisation of behaviour
by self-report. This study provides insight into the specificity of
proximal social and behavioural factors as correlates of metabolic
phenotypes underlying diabetes development. The findings have
implications for tailoring diabetes prevention programs in
communities and specific interventions in individuals with
different phenotype expression. Reducing the frequency of SDB
symptoms may be effective in reducing the expression of the
three latent phenotypes that most strongly predict diabetes
development. Moreover, management of optimal sleep duration
may have added benefits for the glycaemic regulation across the
full continuum of metabolic health. These hypotheses require
prospective examination due to the possibility of reverse causality
despite the stratification used in this study.
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